2020
Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy
Guo F, Song X, Li Y, Guan W, Pan W, Yu W, Li T, Hsieh E. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Osteoporosis International 2020, 32: 321-332. PMID: 32803316, PMCID: PMC9509525, DOI: 10.1007/s00198-020-05584-w.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateLong-term clinical managementBone mineral density lossMineral density lossAntiretroviral therapyDisoproxil fumarateClinical managementRisk factorsGreater bone mineral density lossInitiation of TDFDual-energy x-ray absorptiometry testingHIV-specific parametersNon-TDF groupUndetectable viral loadOutpatient HIV clinicRelated risk factorsLarge tertiary hospitalBone mineral densityDensity lossAntiretroviral initiationTDF groupWeek 96HIV clinicWeek 48HIV diagnosis
2016
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016, 30: 1935-1942. PMID: 27124896, PMCID: PMC4949136, DOI: 10.1097/qad.0000000000001131.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateVitamin DProcollagen type 1 N-terminal propeptideInitiation of TDFTenofovir/lamivudine/efavirenzVitamin D binding protein (VDBP) levelsCollagen type 1 cross-linked C-telopeptideIntact parathyroid hormone levelsCross-linked C-telopeptideIntact parathyroid hormoneParathyroid hormone levelsTotal procollagen type 1 N-terminal propeptideBinding protein levelsProtein levelsMulticenter clinical trialPlasma samplesOngoing multicenter clinical trialsN-terminal propeptideClinical characteristicsParathyroid hormoneBone lossFormation markersDisoproxil fumarateC-telopeptideBone resorptionWhich HIV patients should be screened for osteoporosis
Alvarez E, Belloso WH, Boyd MA, Inkaya AÇ, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW. Which HIV patients should be screened for osteoporosis. Current Opinion In HIV And AIDS 2016, 11: 268-276. PMID: 26895510, DOI: 10.1097/coh.0000000000000269.Peer-Reviewed Original ResearchConceptsBone mineral densityLow bone mineral densityFracture Risk Assessment ToolMeasurement of BMDDual-energy X-ray absorptiometryEnergy X-ray absorptiometryImpact of comorbiditiesManagement of osteoporosisTenofovir disoproxil fumarateX-ray absorptiometryLong-term managementRisk assessment toolHIV physiciansHIV patientsConsensus guidelinesDisoproxil fumaratePhysicians' knowledgeRisk factorsMineral densityCare differsGeneral populationClinical approachPLWHOverall risk estimationSubstance abuse